Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar JoeArizona (38.83) Submitted: 2/18/2013 5:38:25 PM : Outperform Start Price: $4.74 EXEL Score: -107.48

Clinical trials are ongoing, and I don't anticipate much growth until the current round of trials show conclusive evidence that Cabozantinib is effective. But they already have one FDA approval under their belt, and as more come in the next few years, EXEL will take off.

Featured Broker Partners


Advertisement